The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The potential of the human CD38-specific antibody daratumumab to improve the antimyeloma effect of novel multidrug therapies including patients refractory to lenalidomide or bortezomib.
T. Mutis
Research Funding - Genmab
M. de Weers
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
M. S. van der Veer
No relevant relationships to disclose
B. v. Kessel
No relevant relationships to disclose
J. M. Bakker
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
S. Wittebol
No relevant relationships to disclose
P. Parren
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
H. M. Lokhorst
Research Funding - Genmab